JBIO Jade Biosciences, Inc.
Price Chart
Executive Summary
Jade Biosciences reported interim Phase 1 data for JADE101, an anti-APRIL antibody for IgAN. The data showed ~70% mean IgA reduction sustained at 12 weeks at the 700 mg dose, a favorable safety profile, and PK/PD modeling supports every-12-week subcutaneous maintenance dosing. This supports advancing to Phase 2 (JUNIPER, already started) and a planned registrational Phase 3 trial in 1H 2027. The positive clinical data de-risks the program and supports best-in-class positioning in a large $20B+ addressable market.
Actionable Insight
The Phase 1 data strongly supports JADE101's best-in-class potential with Q12W dosing, a key competitive advantage. Monitor JUNIPER Phase 2 interim data expected in 2027 for UPCR-24 results and the planned Phase 3 start in 1H 2027. The stock likely re-rates on pipeline de-risking; watch for near-term volatility from analyst assessments of cross-trial comparisons vs sibeprenlimab/povetacicept.
Key Facts
- Mean IgA reductions ~70% from baseline sustained at 12 weeks at 700 mg dose
- Phase 1 healthy volunteer trial (N=32): well-tolerated up to 1,400 mg, no serious adverse events, no discontinuations, no hypogammaglobulinemia
- IgA-lowering potency ~379-fold higher than sibeprenlimab, ~26-fold higher than povetacicept (cross-study comparison)
- Half-life at steady state ~24.2 days, ~8.7-fold longer than povetacicept, ~2.6-fold longer than sibeprenlimab
- Phase 2 IgAN trial (JUNIPER) initiated, interim data expected 2027
- Registrational Phase 3 trial planned for first half of 2027
- Cash of $311 million as of March 31, 2026; runway into 1H 2028
- Company estimates IgAN as $20B+ potential U.S. market alone
Financial Impact
No revenue or financial guidance provided; $311M cash position supports development into 1H 2028
Risk Factors
- Interim Phase 1 data in healthy volunteers may not fully translate to IgAN patients
- Cross-study comparisons to competitors are not head-to-head and may overstate differentiation
- Phase 2/3 clinical or regulatory delays could push timelines
- IgAN is a competitive landscape with multiple anti-APRIL/BAFF agents in development
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-249763 |
| Document: d124589dex991.htm | 0001193125-26-249763 |
| Document: 0001193125-26-249763-index-headers.html | 0001193125-26-249763 |
| Document: 0001193125-26-249763-index.html | 0001193125-26-249763 |
| Document: 0001193125-26-249763.txt | 0001193125-26-249763 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
7d ago
|
Press Release
| $16.91 awaiting T+1 | awaiting T+1 | — | $15.34 (+9.28%) |
|
Jun 4, 2026
8d ago
|
8-K
| $17.52 awaiting T+1 | awaiting T+1 | — | $15.34 (+12.44%) |
|
Jun 4, 2026
8d ago
|
424B5
| $17.52 awaiting T+1 | awaiting T+1 | — | $15.34 (+12.44%) |
|
Jun 4, 2026
9d ago
|
Press Release
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.91% | $15.34 (+13.53%) |
|
Jun 3, 2026
9d ago
|
424B5
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.94% | $15.34 (+13.53%) |
|
Jun 3, 2026
9d ago
|
Press Release
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.94% | $15.34 (+13.53%) |
|
Jun 1, 2026
11d ago
|
8-K
| $18.59 $17.75 | ▼ −4.52% | ▼ −4.66% | $15.34 (−17.48%) |
|
May 26, 2026
17d ago
|
Press Release
| $21.50 $20.84 | ▼ −3.07% | ▼ −3.62% | $15.34 (−28.65%) |
|
May 18, 2026
26d ago
|
EFFECT
| $22.01 $21.88 | ▲ +0.59% | ▼ −0.06% | $15.34 (+30.30%) |
|
May 7, 2026
5w ago
|
S-3
| $25.81 $24.86 | ▲ +3.68% | ▲ +3.91% | $15.34 (+40.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access